Structure Therapeutics Inc ADR
Structure Therapeutics Inc ADR (GPCR) Implied Volatility Current
GPCR implied volatility is 62%. IV Rank is 2%, placing current premiums in the bottom of their 52-week range.
Read more
Tracking GPCR implied volatility helps you identify when options premiums on Structure Therapeutics Inc ADR are historically cheap or expensive, and where the best trades are hiding. Structure Therapeutics Inc ADR implied volatility reflects the market's expectation of future price movement: when GPCR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Structure Therapeutics Inc ADR's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For GPCR, tracking metrics like GPCR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on GPCR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where GPCR implied volatility sits today versus where it has been. Our scanner ranks Structure Therapeutics Inc ADR implied volatility against its historical range, surfaces extremes in GPCR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Structure Therapeutics Inc ADR IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is compressed vs the past year - options are relatively cheap, favoring buyers.
As of September 18, 2026
Trade options with IV on your side
Track GPCR IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→